EcoDrugPlus

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSOJAG00000000937
Gene Symbol: PSMA4
1 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSOJAG00000014989
Gene Symbol: PSMA5
1 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Alpha 6a

Ensembl ID : ENSOJAG00000020703
Gene Symbol: PSMA6A
1 Cross references
244 Possible Orthologues:

Proteasome 20s Subunit Alpha 6b

Ensembl ID : ENSOJAG00000008411
Gene Symbol: PSMA6B
1 Cross references
278 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSOJAG00000010085
Gene Symbol: PSMA8
1 Cross references
182 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSOJAG00000022544
Gene Symbol: PSMB1
1 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSOJAG00000015797
Gene Symbol: PSMB10
1 Cross references
171 Possible Orthologues:

Proteasome 20s Subunit Beta 11b

Ensembl ID : ENSOJAG00000020432
Gene Symbol: PSMB11B
1 Cross references
159 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSOJAG00000017149
Gene Symbol: PSMB2
1 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSOJAG00000011353
Gene Symbol: PSMB3
1 Cross references
260 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSOJAG00000016563
Gene Symbol: PSMB4
1 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSOJAG00000011146
Gene Symbol: PSMB5
1 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).